[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Kudva R, Perveen S, Janardhana A: Primary epithelioid angiosarcoma of bone: a case report with immunohistochemical study. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):811-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelioid angiosarcoma of bone: a case report with immunohistochemical study.
  • Primary malignant vascular tumors of the bone are exceedingly rare and represent <1% of primary malignant bone tumors.
  • Angiosarcoma is a malignant mesenchymal neoplasm in which the neoplastic cells demonstrate endothelial differentiation.
  • EA is an aggressive tumor with poor prognosis.
  • He was treated with amputation and chemotherapy.
  • After 1 month of chemotherapy, he developed pleural effusion and died.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Hemangiosarcoma / diagnosis. Hemangiosarcoma / pathology. Sarcoma / diagnosis. Sarcoma / pathology. Tibia / pathology
  • [MeSH-minor] Amputation. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Drug Therapy / methods. Fatal Outcome. Histocytochemistry. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045426.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents
  •  go-up   go-down


2. Schmidmaier R, Mörsdorf K, Baumann P, Emmerich B, Meinhardt G: Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers; 2006 Oct-Dec;21(4):218-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo.
  • BACKGROUND/AIMS: Multiple myeloma is an incurable disease and patients eventually die of disease progression due to drug resistance.
  • VLA-4 (very late antigen 4), VCAM (vascular adhesion molecule), LFA-1 (leukocyte function-associated antigen 1), and ICAM-1 (intercellular adhesion molecule 1)-mediated adhesion of myeloma cells to bone marrow stromal cells induces primary multidrug resistance in vitro.
  • Based on these preclinical data we hypothesized that myeloma cells with strong adhesion - due to strong expression of adhesion molecules on the cell surface - are selected by chemotherapy in patients.
  • The patients were either at diagnosis (chemo-naive; n=17) or at relapse (pre-treated; n=15).
  • Furthermore, the response to the next chemotherapy of chemo-naive patients was correlated with the expression levels of adhesion molecules.
  • RESULTS: ICAM-1, VLA-4, and VCAM expression was higher in pre-treated patients than in chemo-naive patients and the expression levels increased with the number of chemotherapy regimens.
  • CONCLUSION: This study suggests that multiple myeloma cells expressing high levels of VLA-4 and ICAM-1 are drug resistant and that such a subpopulation of cells is selected by chemotherapy.
  • [MeSH-major] Cell Adhesion Molecules / analysis. Multiple Myeloma / drug therapy
  • [MeSH-minor] ADP-ribosyl Cyclase 1 / analysis. Cell Adhesion. Drug Resistance, Neoplasm. Female. Humans. Integrin alpha4beta1 / analysis. Intercellular Adhesion Molecule-1 / analysis. Lymphocyte Function-Associated Antigen-1 / analysis. Male. Membrane Glycoproteins / analysis. Middle Aged. Syndecan-1 / analysis. Vascular Cell Adhesion Molecule-1 / analysis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177159.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Integrin alpha4beta1; 0 / Lymphocyte Function-Associated Antigen-1; 0 / Membrane Glycoproteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1; EC 3.2.2.5 / CD38 protein, human; EC 3.2.2.6 / ADP-ribosyl Cyclase 1
  •  go-up   go-down


3. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To our knowledge, this is the first description of a total en bloc spondylectomy through a posterior approach for the treatment of an intraosseous metastatic meningioma to the eleventh dorsal vertebra.
  • By the end on 2003 he developed progressively invalidating dorsolumbar pain.
  • The pathological specimen was identified as adenocarcinoma and he initiated chemotherapy.
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • In June 2004 he underwent T11 total en bloc spondylectomy (Tomita's procedure), fusion with bone and calcium substitute-filled stackable carbon-fiber cages, and T9 to L1 transpedicular screw fixation.
  • The ability to metastatize seems to be linked to vascular or lifatic invasiveness.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Scudla V, Pika T, Budikova M, Petrova J, Minarik J, Bacovsky J, Langova K, Zivna J, Czech Myeloma Group: The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma; 2010;57(2):102-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma.
  • The study aimed at evaluating the relation of 7 parameters associated with the internal biological properties of myeloma cells and the bone marrow microenvironment to multiple myeloma (MM) stages, distinguishing its initial/asymptomatic phase from monoclonal gammopathy of undetermined significance (MGUS) and assessing their relation to myeloma prognosis.
  • In the studied group comprising 286 individuals (89 MGUS and 179 MM patients), statistically significant differences (Mann-Whitney test) between MGUS and MM at the time of diagnosis were found in the serum levels of HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), ICTP (intercellular - carboxy-terminal telopeptide of type I collagen), PINP (procollagen type I N-terminal propeptide), OPG (osteoprotegerin) and syndecan-1/CD138, but not in Fas.
  • The assessment of initial values of HGF, VEGF, ICTP, PINP, OPG, syndecan-1 and Fas showed a statistically significant relation (log rank test) to the overall survival (OS) in a group of 132 patients treated with conventional chemotherapy only in the cases of syndecan-1 (p=0.0002) and Fas (p=0.018), but in none of the investigated parameters in a group of 74 patients treated with HDT/ASCT (high-dose therapy/autologous stem cell transplantation).
  • Despite the positive relation, especially of syndecan-1 and, to a lesser extent, of Fas to the OS in patients treated with conventional chemotherapy, these prognostic factors are not applicable to HDT/ASCT.
  • [MeSH-major] Biomarkers, Tumor / blood. Multiple Myeloma / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Collagen Type I. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Hepatocyte Growth Factor / blood. Humans. Male. Middle Aged. Monoclonal Gammopathy of Undetermined Significance / blood. Monoclonal Gammopathy of Undetermined Significance / diagnosis. Neoplasm Staging. Osteoprotegerin / blood. Peptide Fragments / blood. Peptides. Procollagen / blood. Prognosis. Syndecan-1 / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099972.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / HGF protein, human; 0 / Osteoprotegerin; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / TNFRSF11B protein, human; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / collagen type I trimeric cross-linked peptide; 0 / procollagen Type I N-terminal peptide; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


5. Shimamoto T, Hayashi S, Ando K, Yguchi M, Miyazawa K, Kimura Y, Mukai K, Serizawa H, Ohyashiki K: Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy. Am J Hematol; 2001 Jan;66(1):49-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy.
  • We report a patient with anaplastic large-cell lymphoma (ALCL) who has been given immunosuppressive therapy for Evans syndrome for 10 years.
  • Examination of biopsy specimens obtained by para-aortic lymph nodes and liver masses resulted in a diagnosis of ALCL.
  • Bone marrow aspiration demonstrated the invasion of giant neoplastic cells and trilineage myelodysplasia.
  • He was treated with combination chemotherapy (ABVD regimen), achieving complete remission.
  • Myelodysplasia and serum IL-6 and VEGF also normalized after treatment.
  • We assumed that ALCL resulted from long-term immunosuppressive therapy and that the up-regulation of IL-6 and VEGF played a role in pathogenesis of this type of lymphoma.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Cyclosporine / adverse effects. Endothelial Growth Factors / blood. Immunosuppressive Agents / adverse effects. Interleukin-6 / blood. Lymphokines / blood. Lymphoma, Large B-Cell, Diffuse / drug therapy. Myelodysplastic Syndromes / etiology. Pancytopenia / drug therapy. Prednisolone / adverse effects
  • [MeSH-minor] Abdominal Pain / etiology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bone Marrow / pathology. CD4-CD8 Ratio. Cell Lineage. Combined Modality Therapy. DNA, Neoplasm / analysis. DNA, Viral / analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Fever / etiology. Fibroblast Growth Factor 2 / blood. Gene Rearrangement, B-Lymphocyte. Humans. Immunocompromised Host. Inflammation. Lymph Nodes / pathology. Male. Middle Aged. Remission Induction. Splenectomy. Syndrome. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426493.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral; 0 / Endothelial Growth Factors; 0 / Immunosuppressive Agents; 0 / Interleukin-6; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone; ABVD protocol
  •  go-up   go-down


6. Yasuda M, Akiyama N, Miyamoto S, Warabi M, Takahama Y, Kitamura M, Yakushiji F, Kinoshita H: Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma. Pituitary; 2010;13(1):39-47
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma.
  • Lymphoma is one of the causative factors of hypothalamus-pituitary dysfunction, and intravascular large B-cell lymphoma (IVLBCL) is a subtype of primary extranodal neoplasm.
  • Though we conducted systemic investigations including chest and abdomen enhanced computer tomography, transbronchial lung biopsy, and bone marrow biopsy, the diagnosis was not confirmed.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cranial Nerves / physiology. Cranial Nerves / physiopathology. Female. Humans. Neoplasms, Second Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):311-6 [10090680.001]
  • [Cites] Endocr J. 2005 Oct;52(5):543-9 [16284431.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):112-23 [2420221.001]
  • [Cites] Am J Med. 1999 Aug;107(2):169-76 [10460050.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3168-73 [17577023.001]
  • [Cites] Acta Neurochir (Wien). 2008 Aug;150(8):833-6 [18574548.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Pituitary. 2011 Jun;14 (2):194-7 [19123039.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1525-7 [18053461.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] Australas Radiol. 2000 Feb;44(1):112-4 [10761271.001]
  • [Cites] Am J Clin Pathol. 1979 Jun;71(6):724-7 [377944.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):46-9 [19229666.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Pituitary. 2009;12(1):76-9 [18205050.001]
  • [Cites] Am J Med. 1996 Nov;101(5):563-4 [8948282.001]
  • [Cites] Endocr Pract. 2003 Jul-Aug;9(4):296-300 [14561574.001]
  • [Cites] Wien Klin Wochenschr. 2006 Jul;118(13-14):422-5 [16865648.001]
  • [Cites] Am J Med Sci. 2004 Aug;328(2):124-8 [15311173.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):231-2 [10706771.001]
  • [Cites] Histopathology. 1997 Aug;31(2):161-6 [9279568.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):335-341 [12114795.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):236-44 [18081700.001]
  • [Cites] J R Soc Med. 1997 May;90(5):274-5 [9204025.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):236-9 [15224358.001]
  • [Cites] Folia Neuropathol. 2007;45(3):144-8 [17849366.001]
  • [Cites] Rinsho Shinkeigaku. 1999 Nov;39(11):1160-3 [10689943.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 Jan;38(1):34-8 [10723949.001]
  • [Cites] No To Shinkei. 1998 Dec;50(12):1133-41 [9989361.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):88-91 [8225384.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):861-8 [8078533.001]
  • [Cites] Dermatology. 2004;209(2):135-7 [15316168.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):246-50 [12480233.001]
  • [Cites] No Shinkei Geka. 1998 Jan;26(1):53-8 [9488992.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1611-6 [15370213.001]
  • [Cites] Medicine (Baltimore). 1999 Jul;78(4):236-69 [10424206.001]
  • [Cites] Med Pediatr Oncol. 2001 Mar;36(3):392-5 [11241445.001]
  • [Cites] Cas Lek Cesk. 2008;147(11):569-73 [19097361.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):227-31 [15072472.001]
  • [Cites] Blood. 2007 Jan 15;109(2):478-85 [16985183.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3189-95 [18506023.001]
  • [Cites] Endocrine. 2008 Aug-Dec;34(1-3):11-6 [18937075.001]
  • [Cites] J Clin Neurosci. 2008 Oct;15(10):1148-51 [18653342.001]
  • (PMID = 19707877.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


7. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J: Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer; 2006 Nov 1;107(9):2108-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.
  • Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown etiology and a variable natural course.
  • The authors present a comprehensive review of the literature on HEH with a focus on clinical outcome after different therapeutic strategies.
  • The reviewed parameters included demographic data, clinical manifestations, therapeutic modalities, and clinical outcome.
  • Most patients presented with multifocal tumor that involved both lobes of the liver.
  • Lung, peritoneum, lymph nodes, and bone were the most common sites of extrahepatic involvement at the time of diagnosis.
  • The most common management has been liver transplantation (LTx) (44.8% of patients), followed by no treatment (24.8% of patients), chemotherapy or radiotherapy (21% of patients), and liver resection (LRx) (9.4% of patients).
  • The 1-year and 5-year patient survival rates were 96% and 54.5%, respectively, after LTx; 39.3% and 4.5%, respectively, after no treatment, 73.3% and 30%, respectively, after chemotherapy or radiotherapy; and 100% and 75%, respectively, after LRx.
  • LRx has been the treatment of choice in patients with resectable HEH.
  • However, LTx has been proposed as the treatment of choice because of the hepatic multicentricity of HEH.
  • The role of different adjuvant therapies for patients with HEH remains to be determined.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / diagnosis. Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Female. Hepatectomy. Humans. Liver Transplantation. Male. Neoplasm Metastasis. Survival Rate

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17019735.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


8. Fernández Y, Bernabeu-Wittel M, García-Morillo JS: Kaposiform hemangioendothelioma. Eur J Intern Med; 2009 Mar;20(2):106-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive vascular neoplasm that mainly occurs during childhood.
  • It generally originates on the skin, usually affecting deeper tissue by infiltrative growth.
  • Although visceral involvement is very uncommon, several cases with bone, retroperitoneal, or mediastinal involvement have been described.
  • On the other hand, bulk visceral masses lead to a 40-50% mortality rate, mainly due to progressive failure of the infiltrated organ(s), in spite of interferon, glucocorticoids, and combined chemotherapy.
  • In conclusion, the onset of a consumptive coagulopathy following the presence of a vascular tumor, in children as well as in older patients, should spark suspicion of KHE, among other entities.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / therapy

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Kaposiform Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327597.001).
  • [ISSN] 1879-0828
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 87
  •  go-up   go-down


9. Kiyohara T, Kumakiri M, Kobayashi H, Shimizu T, Ohkawara A, Ohnuki M: A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. J Cutan Pathol; 2000 Sep;27(8):413-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second biopsy revealed emboli of atypical lymphocytes within many of the dilated and proliferated vessels in the deep dermis and subcutaneous tissue.
  • These findings confirmed the diagnosis of intravascular large B-cell lymphoma.
  • A laboratory examination showed a high level of LDH and abnormal cells in the bone marrow.
  • Before the treatment, the size of the nodules decreased spontaneously by about 50% in one month and significantly in two months.
  • Although combination chemotherapy, which consisted of CHOP, brought her partial remission, she experienced neurological symptoms 6 months after the initial treatment and died of brain metastasis 9 months after the treatment.
  • 1) the first biopsy revealed non-specific findings compatible with erythema nodosum; and 2) before the treatment, the nodules regressed spontaneously.
  • [MeSH-major] Erythema Nodosum / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasm Regression, Spontaneous / pathology. Neoplasms, Vascular Tissue / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Middle Aged. Skin / blood supply. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955689.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] DENMARK
  •  go-up   go-down


10. Parrens M, Dubus P, Agape P, Rizcallah E, Marit G, de Mascarel A, Merlio JP: Intrasinusoidal bone marrow infiltration revealing intravascular lymphomatosis. Leuk Lymphoma; 2000 Mar;37(1-2):219-23
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrasinusoidal bone marrow infiltration revealing intravascular lymphomatosis.
  • We report a case of intravascular lymphomatosis with an exceptional clinical presentation showing splenomegaly combined with early bone marrow involvement.
  • The diagnosis was made on bone marrow biopsy examination using both immunohistochemistry and molecular biology analysis.
  • We stress the histopathological features of bone marrow involvement by intravascular lymphoma which allow the prompt recognition of this disease.
  • Early systemic chemotherapy, which represents the only chance of remission in such an aggressive disease, can then be initiated.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Lymphoma / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD20. Fatal Outcome. Female. Gene Rearrangement, T-Lymphocyte. Genes, T-Cell Receptor gamma / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Neoplasm Invasiveness. Polymerase Chain Reaction. Splenomegaly / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10721790.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


11. Rakha EA, Gill MS, El-Sayed ME, Khan MM, Hodi Z, Blamey RW, Evans AJ, Lee AH, Ellis IO: The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat; 2009 Mar;114(2):243-50
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positive lymph nodes (LN) were found in 41% and definite vascular invasion (VI) in 26% of the cases.
  • The majority of tumours were predominantly (>50 of tumour area) of ductal type (57%).
  • There was an association between histologic type of carcinoma in LN metastasis and the predominant histologic type of the primary tumour.
  • Mixed tumours showed metastatic patterns similar to that of ILC with frequent metastasis to bone.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404368.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Stauffer JK, Khan T, Salcedo R, Hixon JA, Lincoln E, Back TC, Wigginton JM: Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors. J Immunother; 2006 Mar-Apr;29(2):151-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis of patients with advanced neuroblastoma is poor overall despite standard therapeutic modalities and has stimulated substantial interest in the potential role for biologics such as immunotherapeutic and/or antiangiogenic agents for the treatment of neuroblastoma.
  • To facilitate preclinical investigation of the efficacy and mechanisms of action of new biologic agents for the treatment of neuroblastoma, a comprehensive panel of disease-specific fluorescence-based model systems has been developed by our group to image the growth, neovascularization, metastasis, and apoptosis of neuroblastoma tumors.
  • These model systems use fluorescent proteins to monitor cytokine-induced alterations in the growth and metastasis of neuroblastoma and allow for monitoring and/or quantitation of even minimal residual disease that is localized to visceral organ sites such as the liver, lung, and/or bone marrow.
  • Further, based on the differential spectra of red fluorescent protein, green fluorescent protein (GFP), and agents such as 4'-6-diamidino-2-phenylindole (DAPI) (blue) and fluorescein isothiocyanate-dextran (green), multicolor systems have now been established by our group that allow for combined assessment of parameters, including the macroscopic relation of tumors to their associated vasculature and, within tissue sections, simultaneous quantitation of tumor neovascularization and evaluation of therapy-induced apoptosis within the tumor and vascular endothelial compartments.
  • Collectively, these model systems provide important tools for investigation of the biology of neuroblastoma tumors and evaluation of mechanisms that mediate the regression of these tumors in response to novel therapeutic agents, including cytokines such as interleukin-12.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Diagnostic Imaging / methods. Interleukin-12 / administration & dosage. Neuroblastoma / diagnosis. Neuroblastoma / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cytokines / administration & dosage. Cytokines / therapeutic use. Dextrans. Fluorescein-5-isothiocyanate / analogs & derivatives. Fluorescence. Green Fluorescent Proteins. Indoles. Luminescent Proteins. Male. Mice. Mice, Inbred C57BL. Neoplasm Metastasis. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531816.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cytokines; 0 / Indoles; 0 / Luminescent Proteins; 0 / fluorescein isothiocyanate dextran; 0 / red fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 187348-17-0 / Interleukin-12; 47165-04-8 / DAPI; I223NX31W9 / Fluorescein-5-isothiocyanate; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


13. Fatusi OA, Owotade FJ, Ojo OS: Maxillary haemangiopericytoma: a case report. West Afr J Med; 2004 Apr-Jun;23(2):180-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Haemangiopericytoma is a very rare slow-growing vascular tumour with a variable malignant potential, constituting less than 1% of all neoplasms.
  • Primary haemangiopericytoma of bone is even rarer, constituting about 0.1% of bone tumours.
  • Chemotherapy has no known role in the management of haemangiopericytoma.
  • Postoperative radiation therapy appears to be effective against tumour recurrence.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Maxillary Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Biopsy. Fatal Outcome. Female. Hospitals, University. Humans. Nigeria / epidemiology. Precipitating Factors. Prognosis. Radiotherapy, Adjuvant. Rare Diseases / diagnosis. Rare Diseases / epidemiology. Rare Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15287302.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


14. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We propose the hypothesis that vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) play pathologic roles in the development of ectopic bone formation in pyogenic granuloma.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


15. Miura S, Meirmanov S, Nakashima M, Hayashi T, Abe K, Tamaru N, Miyahara Y, Sekine I: Intimal sarcoma of the pulmonary artery: report of an autopsy case. Pathol Res Pract; 2005;201(6):469-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are easily misdiagnosed as chronic pulmonary embolism, mediastinal mass or tumor emboli, which delay a proper treatment.
  • Although the advanced technologies are now increasingly being used, their diagnosis is usually hard to establish preoperatively at the present time.
  • Although a PAS had been suspected, the final diagnosis of pulmonary intimal sarcoma was made only postoperatively by histological and immunohistochemical examination.
  • The patient died 8 months after the operation because of tumor growth progression, despite adjuvant chemotherapy and radiation therapy.
  • However, the diagnosis of leiomyosarcoma should not be made on the basis of immunostains in the absence of typical morphologic features, and PAS, like the present case, should be more appropriately classified as intimal sarcoma according to the new WHO Classification of Tumours of Soft Tissue and Bone published in 2002.
  • [MeSH-major] Lung Neoplasms / secondary. Pulmonary Artery / pathology. Sarcoma / secondary. Tunica Intima / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Endarterectomy. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136754.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Anghel G, Petrinato G, Severino A, Remotti D, Insabato L, De Renzo A, Rotoli B, Majolino I: Intravascular B-cell lymphoma: report of two cases with different clinical presentation but rapid central nervous system involvement. Leuk Lymphoma; 2003 Aug;44(8):1353-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor is of B-cell origin in most cases.
  • The first was that of a 55-year-old woman with a large B-cell lymphoma of the leg, successfully treated with conventional chemotherapy (CHT) followed by autologous peripheral stem cell transplantation.
  • She died before any specific treatment, and post-mortem examination revealed the intravascular proliferation of lymphoma B-cells in the brain and bone marrow.
  • The second case was that of a 60-year-old male with CNS involvement at diagnosis.
  • He responded poorly to CHOP-like CHT, and died 2 months after diagnosis and 6 months after onset of symptoms.
  • Failure of CHT at least in some IVL patients may be related to a delay in the initiation of therapy due to non-specific neurological symptoms.
  • Therefore, early diagnosis based upon aggressive attempts immediately followed by adequate therapy may prove beneficial to these patients.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Autopsy. Fatal Outcome. Female. Humans. Leg / blood supply. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12952229.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 38
  •  go-up   go-down


17. Ohshima R, Tomita N, Motohashi K, Ieda A, Hyou R, Fujisawa S, Fujita H, Sakai R, Koharazawa H, Kuwabara H, Kanamori H, Ishigatsubo Y: [Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive]. Rinsho Ketsueki; 2005 Jun;46(6):453-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We retrospectively evaluated the diagnosis and clinical courses of 8 patients with intravascular large B-cell lymphoma (IVL) diagnosed while they were alive.
  • Most complaints at diagnosis were fever or dyspnea.
  • The diagnosis of IVL was confirmed by biopsy specimens from the bone marrow in 4, lung in 2, muscle, adrenal gland, and lymph node in 1 case, respectively.
  • Initial bone marrow involvement was found in 6 patients.
  • Chemotherapy was performed in 7 patients.
  • Rituximab was added to chemotherapy in 5 patients.
  • In suspicious cases, it is important to bear IVL in mind and examine bone marrow biopsies for an early diagnosis.
  • In addition, it is suggested that Rituximab may play only a temporary role in the treatment of IVL.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447727.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 17
  •  go-up   go-down


18. Mahmood A, Cleasby M, Hübscher SG, Khaira HS: Ewing's sarcoma of the inferior vena cava. Vasc Endovascular Surg; 2009 Aug-Sep;43(4):403-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing's sarcoma most commonly arises from bone but may also arise from soft tissues.
  • Sarcoma of the inferior vena cava is a rare entity that requires multimodal therapy including surgical resection and vascular reconstruction.
  • [MeSH-major] Sarcoma, Ewing / secondary. Vascular Neoplasms / diagnosis. Vena Cava, Inferior / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19351649.001).
  • [ISSN] 1538-5744
  • [Journal-full-title] Vascular and endovascular surgery
  • [ISO-abbreviation] Vasc Endovascular Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Han K, Kahng J, Kim M, Lim J, Kim Y, Cho B, Kim HK, Min WS, Kim CC, Lee KY, Kim BK, Kang CS: Expression of functional markers in acute nonlymphoblastic leukemia. Acta Haematol; 2000;104(4):174-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multidrug resistance parameters, tissue infiltration parameters, receptors for colony-stimulating factors (CSFr) and cell cycle parameters were analyzed using flow cytometry in 145, 109 initial and 36 relapsed or refractory, acute nonlymphoblastic leukemia (ANLL) patients to find out clinically more reliable functional parameters.
  • Complete remission rate after standard chemotherapy falls in PGP-positive cases (p = 0.001).
  • The organ tropism is different depending on the infiltration parameters, vascular cell adhesion molecule to splenomegaly, matrix metalloprotease-2 to hepatomegaly and to extramedullary infiltration other than spleen, liver or lymph node.
  • In conclusion, analysis of these new functional parameters could help to predict and overcome the clinical behavior of each ANLL at the time of diagnosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / metabolism
  • [MeSH-minor] Adolescent. Aged. Antigens, Surface / analysis. Bone Marrow Cells / chemistry. Bone Marrow Cells / metabolism. Cell Adhesion Molecules / analysis. Cell Cycle. Child. Child, Preschool. Drug Resistance, Multiple. Female. Flow Cytometry. Humans. Infant. Male. Middle Aged. Neoplasm Proteins / analysis. Receptors, Colony-Stimulating Factor / analysis. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11279307.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / Receptors, Colony-Stimulating Factor
  •  go-up   go-down


20. Aoki J: [Roles of magnetic resonance imaging in management of bone tumors]. Nihon Igaku Hoshasen Gakkai Zasshi; 2000 May;60(6):295-301
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Roles of magnetic resonance imaging in management of bone tumors].
  • The roles of magnetic resonance imaging (MRI) in the diagnosis and treatment of bone tumors are reviewed.
  • Most bone tumors can be detected on plain radiography or bone scintigraphy.
  • MRI is helpful in detecting tumors that do not destroy bone matrix or suppress reactive bone formation.
  • Detailed analysis by plain radiography is still the most reliable method for differentiating between benign and malignant bone tumors.
  • In characterizing the histologic types of bone tumors, MRI is of some advantage.
  • For example, MRI can demonstrate cartilage matrix, hemoglobin metabolites, vascular components, and fat contents more clearly than conventional radiological techniques.
  • MRI is now indispensable for the preoperative delineation of malignant bone tumors, because of its excellent soft tissue contrast and multiplanar imaging capability.
  • In this article, the guidelines for evaluation of the surgical margin advocated by the JOA Musculo-skeletal Tumor Committee are introduced for radiologists.
  • MRI monitoring of malignant bone tumors after chemotherapy or surgery can reveal change in the size of enhanced areas that may reflect viable tumors.
  • Dynamic MRI is helpful to differentiate recurrent tumors from granulation tissue.
  • [MeSH-major] Bone Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10860379.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 23
  •  go-up   go-down


21. Tancredi A, Puca A, Carbone A: Multifocal cerebral hemangio-endothelioma. Case report and review of the literature. Acta Neurochir (Wien); 2000;142(10):1157-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intracranial hemangio-endotheliomas (HE) are rare vascular tumours that present histological features and biological behaviour of an intermediate malignancy.
  • Total surgical excision of the tumours was obtained; a histological diagnosis of hemangio-endothelioma was made.
  • Five months later, MRI scan showed new intradiploic skull lesions whereas a scintigraphic study revealed multicentric extracranial bone involvement.
  • Treatment based on interferon-alpha (IFN-alpha) administration was undertaken; this produced partial regression of the lesions.
  • CONCLUSIONS: Surgery continues to play the leading role in the treatment of intracranial HE.
  • However, adjuvant therapy with IFN represents a new and well-tolerated therapeutic method for residual intracranial lesions as well as multicentric extracranial disease.
  • [MeSH-major] Brain Neoplasms / drug therapy. Hemangioendothelioma / drug therapy. Interferon-alpha / therapeutic use. Skull Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Neoplasm, Residual. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11129539.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Interferon-alpha
  • [Number-of-references] 18
  •  go-up   go-down


22. Nakazato T, Suzuki K, Mihara A, Sanada Y, Yoshida S, Kakimoto T: [Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. Rinsho Ketsueki; 2010 Feb;51(2):148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant lymphoma was suspected, but histological diagnosis was difficult because superficial lymph nodes could not be palpated.
  • Histological examination of the bone marrow biopsy specimen demonstrated the proliferation of large atypical lymphoid cells positive for CD20 and CD79a in the small capillaries, leading to the diagnosis of intravascular large B-cell lymphoma (IVLBCL).
  • We chose R-hyper-CVAD/R-MTX-Ara-C alternating therapy with MTX intrathecal injection because CNS involvement in IVLBCL was highly suspected, and she responded well.
  • R-hyper-CVAD/R-MTX-Ara-C alternating therapy was effective in an IVLBCL patient with CNS involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Middle Aged. Neoplasm Invasiveness. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379108.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  •  go-up   go-down






Advertisement